Dose-dependency in local disposition of 5-fluorouracil under non-steady- state condition in rat liver

Journal of Pharmaceutical Sciences

Volumn 89, Issue 1, 2000, Pages 100-107

  Higashimori, Mitsuo ^a   Yamaoka, Kiyoshi ^a   Nakagawa, Terumichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; DRUG DISPOSITION; DRUG ELIMINATION; MALE; NONHUMAN; RAT;

EID: 0033960214     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6017(200001)89:1<100::AID-JPS10>3.0.CO;2-L     Document Type: Article

References (24)

1. Diasio RB, Harris BE. 1989. Clinical pharmacology of 5-fluorouracil. Clin Parmacokinet 16:215-237.
2. Shiotani T, Weber G. 1981. Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem 10:219-224.
3. Fujimoto S, Matsuda K, Kikugawa M, Kaneko M, Tamai N. 1991. Effect of vitamin B2 deficiency on rat liver dihydropyrimidine dehydrogenase activity. J Nutr Sci Vitaminol 37:89-98.
4. Ho DH, Townsend L, Luna MA, Bodey GP. 1986. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6:781-784.
5. Lu Z-H, Zhang R, Diasio RB. 1993. Comparison of dihydropyrimidine dehydrogenase from human, rat, pit and cow liver. Biochem Pharmacol 46: 945-952.
6. Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, Schnackerz KD, Gonzalez FJ. 1994. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 269:23192-23196.
7. Warren BS, LaCreta FP, Kernhauser DM, Williams WM. 1987. Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver. Cancer Res 47:5261-5265.
8. Roberts MS, Donaldson JD, Jackett D. 1989. Availablity prediction by hepatic elimination models for Michaelis-Menten kinetics. J Pharmacokin Biopharm 17:687-719.
9. Fukumura K, Yamaoka K, Higashimori M, Nakagawa T. 1999. Analysis program based on finite element method, MULTI(FEM), for evaluation of dose-dependent local disposition of drug in liver. J Pharm Sci 88:538-543.
10. Hisaka A, Sugiyama Y. 1999. Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method. J Pharmacokin Biopharm 26:495-519.
11. 131 studies in isolated, perfused rat liver and hind-limb preparations. Diabates 8:307-314.
12. McLean AM, Ruggirello, DA, Banfield C, Gonzalez MA, Bialer M. 1990. Application of a variance-stabilizing transformation approach to linear regression of calibration lines. J Pharm Sci 79: 1005-1008.
13. Yano Y, Yamaoka K, Tanaka H. 1989. A nonlinear least squares program, MULTI(FILT), based on fast inverse Laplace transform for microcomputers. Chem Pharm Bull 37:1035-1038.
14. Yano Y, Yamaoka K, Minamide T, Nakagawa T, Tanaka H. 1990. Evaluation of protain binding effect on local disposition of oxacillin in rat liver by a two-compartment dispersion model. J Pharm Pharmacol 42:632-636.
15. Nishimura M, Yamaoka K, Naito S, Nakagawa T. 1996. Effect of temperature in perfusate on local hepatic disposition of BOF-4272, a new xanthine oxidase inhibitor. Biol Pharm Bull 19:1197-1202.
16. Stock RJ, Cilento EV, McCuskey RS. 1989. A quantitative study of fluorescein isothiocyanate-dextran transport in the microcirculation of the isolated perfused rat liver. Hepatology 9:75-82.
17. Yasui H, Yamaoka K, Nakagawa T. 1995. New hepatocellular diffusion model for analysis of hepatobiliary transport processes of drugs. J Pharmacokin Biopharm 23:183-203.
18. Danckwerts PV. 1953. Continuous flow systems distribution and residence time. Chem Eng Sci 2:1-13.
19. Yamaoka K, Nakagawa T, Uno T. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharm 6:165-175.
20. Hisaka A, Nakamura T, Sugiyama Y. 1999. Analysis of nonlinear hepatic clearance of a cyclopentapeptide, BQ-123, with the multiple indicator dilution method using the dispersion model. Pharm Res 16:103-109.
21. Blomhoff R, Blomhoff HK, Tolleshaug H, Christensen TB, Berg T. 1985. Uptake and degradation of bovine testes β-galactosidase by parenchymal and nonparenchymal rat liver cells. Int J Biochem 17:1321-1328.
22. Spoelstra EC, Pinedo HM, Dekker H, Peters GJ, Lankelma J. 1991. Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. Cancer Chemother Pharmacol 27:320-325.
23. Lankelma J, Lauresse E, Pinedo HM. 1982. A flow-through tissue culture system with fast dynamic response. Anal Biochem 127:340-345.
24. Czejka M, German J. 1992. The binding of 5-fluorouracil to serum protein fractions, erythrocytes and ghosts under in vitro conditions. 325:69-71.